Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus

Cited by (2,856)

Items 101–200 of 2,856

1. 10. Cardiovascular Disease and Risk Management: <i>Standards of Medical Care in Diabetes—2019</i>
   American Diabetes Association · 2019 · Diabetes Care
2. 10. Cardiovascular Disease and Risk Management: <i>Standards of Medical Care in Diabetes—2021</i>
   American Diabetes Association · 2021 · Diabetes Care
3. Diabetes, hyperglycaemia, and acute ischaemic stroke
   Merel J.A. Luitse, Geert Jan Biessels, Guy E.H.M. Rutten, Laurens Jaap Kappelle · 2012 · The Lancet Neurology
4. 2016 Chinese guidelines for the management of dyslipidemia in adults.
   2018 · Europe PMC (PubMed Central)
5. Interaction between Glucose and Lipid Metabolism: More than Diabetic Dyslipidemia
   Parhofer, Klaus G. · 2015 · Diabetes &amp; Metabolism Journal
6. V Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose
   Hermes Tóros Xavier, Maria Cristina de Oliveira Izar, José Rocha Faria‐Neto, Marcelo Heitor Vieira Assad, V. Z. Rocha, Andrei Carvalho Sposito, F. A. Fonseca, J. E. dos Santos, Rosângela dos Santos, MC Bertolami et al. · 2013 · Arquivos Brasileiros de Cardiologia
7. Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges
   Sampson, Uchechukwu K., Fazio, Sergio, Linton, MacRae F. · 2012 · Current Atherosclerosis Reports
8. Secondary Prevention After Coronary Artery Bypass Graft Surgery
   Alexander Kulik, Marc Ruel, Hani M. Jneid, Thomas Bruce Ferguson, Loren F. Hiratzka, John S. Ikonomidis, Francisco Alejandro López-Jiménez, Sheila M McNallan, Mahesh J. Patel, Veronique Lee Roger et al. · 2015 · Circulation
9. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II
   Beckman, Joshua A., Paneni, Francesco, Cosentino, Francesco, Creager, Mark A. · 2013 · European Heart Journal
10. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2017 executive summary
    Garber, Alan J., Abrahamson, Martin J., Barzilay, Joshua I., Blonde, Lawrence, Bloomgarden, Zachary T., Bush, Michael A., Dagogo-Jack, Samuel, DeFronzo, Ralph A., Einhorn, Daniel, Fonseca, Vivian A. et al. · 2017 · Endocrine Practice
11. Effect of Naturally Random Allocation to Lower Low-Density Lipoprotein Cholesterol on the Risk of Coronary Heart Disease Mediated by Polymorphisms in NPC1L1, HMGCR, or Both
    Ference, Brian A., Majeed, Faisal, Penumetcha, Raju, Flack, John M., Brook, Robert D. · 2015 · Journal of the American College of Cardiology
12. 10. Cardiovascular Disease and Risk Management: <i>Standards of Care in Diabetes—2024</i>
    American Diabetes Association Professional Practice Committee, ElSayed, Nuha A., Aleppo, Grazia, Bannuru, Raveendhara R., Bruemmer, Dennis, Collins, Billy S., Das, Sandeep R., Ekhlaspour, Laya, Hilliard, Marisa E., Johnson, Eric L. et al. · 2024 · Diabetes Care
13. Vascular Complications of Diabetes
    Joshua A. Beckman, Mark A. Creager · 2016 · Circulation Research
14. Diabetes Dyslipidemia
    Jonathan D. Schofield, Yifen Liu, Prasanna Rao‐Balakrishna, Rayaz Ahmed Malik, Handrean Soran · 2016 · Diabetes Therapy
15. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial
    Schwartz, Gregory G., Bessac, Laurence, Berdan, Lisa G., Bhatt, Deepak L., Bittner, Vera, Diaz, Rafael, Goodman, Shaun G., Hanotin, Corinne, Harrington, Robert A., Jukema, J. Wouter et al. · 2014 · American Heart Journal
16. Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid
    Mason, R. Preston, Libby, Peter, Bhatt, Deepak L. · 2020 · Arteriosclerosis, Thrombosis, and Vascular Biology
17. High-density lipoprotein revisited: biological functions and clinical relevance
    von Eckardstein, Arnold, Nordestgaard, Børge G, Remaley, Alan T, Catapano, Alberico L · 2023 · European Heart Journal
18. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials
    Hemmingsen, B., Lund, S. S., Gluud, C., Vaag, A., Almdal, T., Hemmingsen, C., Wetterslev, J. · 2011 · BMJ
19. 2017 EACTS Guidelines on perioperative medication in adult cardiac surgery
    Miguel Sousa‐Uva, Stuart J. Head, Milan Milojevic, Jean‐Philippe Collet, Giovanni Landoni, Manuel Castellà, Joel Dunning, Tómas Guðbjartsson, Nick Linker, Elena Sandoval et al. · 2017 · European Journal of Cardio-Thoracic Surgery
20. Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association
    Fox, Caroline S., Golden, Sherita Hill, Anderson, Cheryl, Bray, George A., Burke, Lora E., de Boer, Ian H., Deedwania, Prakash, Eckel, Robert H., Ershow, Abby G., Fradkin, Judith et al. · 2015 · Circulation
21. Hypertriglyceridaemia and risk of coronary artery disease
    Željko Reiner · 2017 · Nature Reviews Cardiology
22. Distinct but complementary contributions of PPAR isotypes to energy homeostasis
    Vanessa Dubois, Jérôme Eeckhoute, Philippe Lefèbvre, Bart Staels · 2017 · Journal of Clinical Investigation
23. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study
    on behalf of the FIELD Study investigators, Davis, T. M. E., Ting, R., Best, J. D., Donoghoe, M. W., Drury, P. L., Sullivan, D. R., Jenkins, A. J., O’Connell, R. L., Whiting, M. J. et al. · 2011 · Diabetologia
24. Rationale and design of the Cardiovascular Inflammation Reduction Trial: A test of the inflammatory hypothesis of atherothrombosis
    Everett, Brendan M., Pradhan, Aruna D., Solomon, Daniel H., Paynter, Nina, MacFadyen, Jean, Zaharris, Elaine, Gupta, Milan, Clearfield, Michael, Libby, Peter, Hasan, Ahmed A.K. et al. · 2013 · American Heart Journal
25. Diabetes and lipid metabolism
    Vasilios Gabriel Athyros, Michael N. Doumas, Konstantinos P. Imprialos, Konstantinos Stavropoulos, Eleni Georgianou, Alexandra Katsimardou, Asterios I. Karagiannis · 2018 · HORMONES
26. High-Density Lipoprotein Cholesterol and Particle Concentrations, Carotid Atherosclerosis, and Coronary Events
    Rachel H. Mackey, Philip Greenland, David Calvin Goff, Donald M. Lloyd‐Jones, Christopher T. Sibley, Samia Mora · 2012 · Journal of the American College of Cardiology
27. The Role of Triglycerides in Atherosclerosis
    Beatriz Talayero, Frank M. Sacks · 2011 · Current Cardiology Reports
28. HDL-targeted therapies: progress, failures and future
    Kingwell, Bronwyn A., Chapman, M. John, Kontush, Anatol, Miller, Norman E. · 2014 · Nature Reviews Drug Discovery
29. Lipid Management for the Prevention of Atherosclerotic Cardiovascular Disease
    Erin D. Michos, John William McEvoy, Roger Scott Blumenthal · 2019 · New England Journal of Medicine
30. An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia
    Scott M. Grundy · 2013 · Journal of clinical lipidology
31. Trajectories of kidney function in diabetes: a clinicopathological update
    Megumi Oshima, Miho Shimizu, Masayuki Yamanouchi, Tadashi Toyama, Akinori Hara, Kengo Furuichi, Takashi Wada · 2021 · Nature Reviews Nephrology
32. Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes
    Ebenezer A. Nyenwe, Terri W. Jerkins, Guillermo E. Umpierrez, Abbas E. Kitabchi · 2010 · Metabolism
33. Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study)
    Ballantyne, Christie M., Bays, Harold E., Kastelein, John J., Stein, Evan, Isaacsohn, Jonathan L., Braeckman, Rene A., Soni, Paresh N. · 2012 · The American Journal of Cardiology
34. Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action
    Bril, Fernando, Cusi, Kenneth · 2017 · Diabetes Care
35. High-density lipoproteins: A consensus statement from the National Lipid Association
    Toth, Peter P., Barter, Philip J., Rosenson, Robert S., Boden, William E., Chapman, M. John, Cuchel, Marina, D'Agostino, Ralph B., Davidson, Michael H., Davidson, W. Sean, Heinecke, Jay W. et al. · 2013 · Journal of Clinical Lipidology
36. Japanese Clinical Practice Guideline for Diabetes 2019
    Eiichi Araki, Atsushi Goto, Tatsuya Kondo, Mitsuhiko Noda, Hiroshi Noto, Hideki Origasa, Haruhiko Osawa, Akihiko Taguchi, Yukio Tanizawa, Kazuyuki Tobe et al. · 2020 · Journal of Diabetes Investigation
37. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025
    American Diabetes Association Professional Practice Committee, ElSayed, Nuha A., McCoy, Rozalina G., Aleppo, Grazia, Balapattabi, Kirthikaa, Beverly, Elizabeth A., Briggs Early, Kathaleen, Bruemmer, Dennis, Das, Sandeep R., Echouffo-Tcheugui, Justin B. et al. · 2025 · Diabetes Care
38. Using Mendelian Randomization to Improve the Design of Randomized Trials
    Ference, Brian A., Holmes, Michael V., Smith, George Davey · 2021 · Cold Spring Harbor Perspectives in Medicine
39. Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association
    Barbara S. Wiggins, Joseph J. Saseen, Robert Lee Page II, Brent N. Reed, Kevin Sneed, John B. Kostis, David E. Lanfear, Salim S. Virani, Pamela Bowe Morris · 2016 · Circulation
40. Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia
    Borén, Jan, Taskinen, Marja-Riitta, Björnson, Elias, Packard, Chris J. · 2022 · Nature Reviews Cardiology
41. 8. Cardiovascular Disease and Risk Management
    American Diabetes Association · 2016 · Diabetes Care
42. Screening for abnormal blood glucose and type 2 diabetes mellitus: U.S. Preventive Services Task Force recommendation statement
    Siu, Albert L., on behalf of the U.S. Preventive Services Task Force* · 2015 · Annals of Internal Medicine
43. Standards of care for type 2 diabetes in China
    Weng, Jianping, Ji, Linong, Jia, Weiping, Lu, Juming, Zhou, Zhiguang, Zou, Dajin, Zhu, Dalong, Chen, Liming, Chen, Li, Guo, Lixin et al. · 2016 · Diabetes/Metabolism Research and Reviews
44. The Effects of Medical Management on the Progression of Diabetic Retinopathy in Persons with Type 2 Diabetes
    Emily Y. Chew, Matthew D. Davis, Ronald P. Danis, James F. Lovato, Letitia Perdue, Craig M. Greven, SAUL M. GENUTH, David Calvin Goff, Lawrence A. Leiter, Faramarz Ismail‐Beigi et al. · 2014 · Ophthalmology
45. Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study
    Pradhan, Aruna D., Paynter, Nina P., Everett, Brendan M., Glynn, Robert J., Amarenco, Pierre, Elam, Marshall, Ginsberg, Henry, Hiatt, William R., Ishibashi, Shun, Koenig, Wolfgang et al. · 2018 · American Heart Journal
46. Triglyceride and HDL-C Dyslipidemia and Risks of Coronary Heart Disease and Ischemic Stroke by Glycemic Dysregulation Status: The Strong Heart Study
    Jennifer S. Lee, Po-Yin Chang, Ying Zhang, Jorge R. Kizer, Lyle G. Best, Barbara V. Howard · 2017 · Diabetes Care
47. Japanese Clinical Practice Guideline for Diabetes 2016
    Masakazu Haneda, Mitsuhiko Noda, Hideki Origasa, Hiroshi Noto, Daisuke Yabe, Yukihiro Fujita, Atsushi Goto, Tatsuya Kondo, Eiichi Araki · 2018 · Diabetology International
48. Assessment and Treatment of Cardiovascular Risk in Prediabetes: Impaired Glucose Tolerance and Impaired Fasting Glucose
    Ralph A. DeFronzo, Muhammad A Abdul‐Ghani · 2011 · The American Journal of Cardiology
49. Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors
    Francque, Sven, Szabo, Gyongyi, Abdelmalek, Manal F., Byrne, Christopher D., Cusi, Kenneth, Dufour, Jean-François, Roden, Michael, Sacks, Frank, Tacke, Frank · 2021 · Nature Reviews Gastroenterology &amp; Hepatology
50. Relationship between Hyperlipidemia, Cardiovascular Disease and Stroke: A Systematic Review
    Aladeen Alloubani, Refat M. Nimer, Rama Samara · 2020 · Current Cardiology Reviews
51. The emerging role of HDL in glucose metabolism
    Drew, Brian G., Rye, Kerry-Anne, Duffy, Stephen J., Barter, Philip, Kingwell, Bronwyn A. · 2012 · Nature Reviews Endocrinology
52. Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials
    Marston, Nicholas A., Giugliano, Robert P., Im, KyungAh, Silverman, Michael G., O’Donoghue, Michelle L., Wiviott, Stephen D., Ference, Brian A., Sabatine, Marc S. · 2019 · Circulation
53. Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association
    Arnold, Suzanne V., Bhatt, Deepak L., Barsness, Gregory W., Beatty, Alexis L., Deedwania, Prakash C., Inzucchi, Silvio E., Kosiborod, Mikhail, Leiter, Lawrence A., Lipska, Kasia J., Newman, Jonathan D. et al. · 2020 · Circulation
54. Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022
    Tomonori Okamura, Kazuhisa Tsukamoto, Hidenori Arai, Yoshio Fujioka, Yasushi Ishigaki, Shinji Koba, Hirotoshi Ohmura, Tetsuo Shoji, Koutaro Yokote, Hiroshi Yoshida et al. · 2023 · Journal of Atherosclerosis and Thrombosis
55. Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance
    Rabar, S., Harker, M., O'Flynn, N., Wierzbicki, A. S., On behalf of the Guideline Development Group · 2014 · BMJ
56. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2019 executive summary.
    Garber, Alan J., Abrahamson, Martin J., Barzilay, Joshua I., Blonde, Lawrence, Bloomgarden, Zachary T., Bush, Michael A., Dagogo-Jack, Samuel, DeFronzo, Ralph A., Einhorn, Daniel, Fonseca, Vivian A. et al. · 2019 · Endocrine Practice
57. Targeting inflammation in metabolic syndrome
    Welty, Francine K., Alfaddagh, Abdulhamied, Elajami, Tarec K. · 2016 · Translational Research
58. Cardiovascular disease risk reduction by raising HDL cholesterol – current therapies and future opportunities
    K Mahdy Ali, Anna Wonnerth, Kurt Huber, Johann Wojta · 2012 · British Journal of Pharmacology
59. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus
    Bianca Hemmingsen, Søren Søgaard Lund, Christian Nyfeldt Gluud, Allan Arthur Vaag, Thomas Almdal, Jørn Wetterslev · 2015 · Cochrane Database of Systematic Reviews · Retracted
60. High-Density Lipoprotein
    Thomas Felix Lüscher, Ulf Landmesser, Arnold von Eckardstein, Alan M. Fogelman · 2014 · Circulation Research
61. Dyslipidemia in Type 2 Diabetes: Prevalence, Pathophysiology, and Management
    Joe M. Chehade, Margaret Gladysz, Arshag D. Mooradian · 2013 · Drugs
62. Cardiomyopathy in obesity, insulin resistance and diabetes
    Michinari Nakamura, Junichi Sadoshima · 2019 · The Journal of Physiology
63. LDL cholesterol: controversies and future therapeutic directions
    Ridker, Paul M · 2014 · The Lancet
64. Pathophysiology and treatment of atherosclerosis
    Sandrin C. Bergheanu, Mathijs C. Bodde, J. Wouter Jukema · 2017 · Netherlands Heart Journal
65. American Association of Clinical Endocrinologists' Comprehensive Diabetes Management Algorithm 2013 Consensus Statement - Executive Summary
    Alan J. Garber, Martin J. Abrahamson, Joshua I. Barzilay, Lawrence Blonde, Zachary T. Bloomgarden, Michael A. Bush, Samuel E. Dagogo-Jack, Michael Davidson, DANIEL F. EINHORN, William Timothy Garvey et al. · 2013 · Endocrine Practice
66. Novel Insights into the Pathogenesis and Management of the Metabolic Syndrome
    Helen H. Wang, Dong Ki Lee, Min Liu, Piero Portincasa, David Q.‐H. Wang · 2020 · Pediatric Gastroenterology Hepatology & Nutrition
67. Evaluating All Potential Oral Complications of Diabetes Mellitus
    Martijn J. L. Verhulst, Bruno G. Loos, Victor E. A. Gerdes, Wijnand J. Teeuw · 2019 · Frontiers in Endocrinology
68. HDL cholesterol: reappraisal of its clinical relevance
    März, Winfried, Kleber, Marcus E., Scharnagl, Hubert, Speer, Timotheus, Zewinger, Stephen, Ritsch, Andreas, Parhofer, Klaus G., von Eckardstein, Arnold, Landmesser, Ulf, Laufs, Ulrich · 2017 · Clinical Research in Cardiology
69. Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey
    RICHARD J. KONES · 2011 · Drug Design Development and Therapy
70. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial
    Margolis, Karen L., O’Connor, Patrick J., Morgan, Timothy M., Buse, John B., Cohen, Robert M., Cushman, William C., Cutler, Jeffrey A., Evans, Gregory W., Gerstein, Hertzel C., Grimm, Richard H. et al. · 2014 · Diabetes Care
71. Effects of Icosapent Ethyl on Total Ischemic Events
    Bhatt, Deepak L., Steg, Ph. Gabriel, Miller, Michael, Brinton, Eliot A., Jacobson, Terry A., Ketchum, Steven B., Doyle, Ralph T., Juliano, Rebecca A., Jiao, Lixia, Granowitz, Craig et al. · 2019 · Journal of the American College of Cardiology
72. New Fibrate Use and Acute Renal Outcomes in Elderly Adults: A Population-Based Study
    Zhao, Ying Y., Weir, Matthew A., Manno, Michael, Cordy, Peter, Gomes, Tara, Hackam, Daniel G., Juurlink, David N., Mamdani, Muhammad, Moist, Louise, Parikh, Chirag R. et al. · 2012 · Annals of Internal Medicine
73. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm - 2020 executive summary
    Handelsman, Yehuda, Jellinger, Paul S., Guerin, Chris K., Bloomgarden, Zachary T., Brinton, Eliot A., Budoff, Matthew J., Davidson, Michael H., Einhorn, Daniel, Fazio, Sergio, Fonseca, Vivian A. et al. · 2020 · Endocrine Practice
74. Cardiac autonomic neuropathy: Risk factors, diagnosis and treatment
    Victoria A Serhiyenko, Alexandr A. Serhiyenko · 2018 · World Journal of Diabetes
75. Hypertriglyceridemia and atherosclerosis
    Jia Peng, Fei Luo, Guiyun Ruan, Ran Peng, Xiangping Li · 2017 · Lipids in Health and Disease
76. Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia
    Zahid Ahmad, Poulabi Banerjee, Sara Hamon, Kuo‐Chen Chan, Aurelie Bouzelmat, William J. Sasiela, Robert C. Pordy, Scott J. Mellis, Hayes M. Dansky, Daniel A. Gipe et al. · 2019 · Circulation
77. Combination lipid therapy in type 2 diabetes
    2010 · New England Journal of Medicine
78. High-density lipoproteins, reverse cholesterol transport and atherogenesis
    Henry J. Pownall, Corina Rosales, Baiba Kurins Gillard, Antonio M. Gotto · 2021 · Nature Reviews Cardiology
79. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia
    Blumenthal, Roger S., Morris, Pamela B., Gaudino, Mario, Johnson, Heather M., Anderson, Timothy S., Bittner, Vera A., Blankstein, Ron, Brewer, LaPrincess C., Cho, Leslie, de Ferranti, Sarah D. et al. · 2026 · JACC
80. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis
    Lee, Meng, Saver, Jeffrey L., Towfighi, Amytis, Chow, Jessica, Ovbiagele, Bruce · 2011 · Atherosclerosis
81. Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease
    Toth, Peter · 2016 · Vascular Health and Risk Management
82. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD – Summary
    pre-diabetes Task Force on diabetes · 2014 · Diabetes and Vascular Disease Research
83. Recent advances in physiological lipoprotein metabolism
    Indra Ramasamy · 2013 · Clinical Chemistry and Laboratory Medicine (CCLM)
84. 8. Cardiovascular Disease and Risk Management
    American Diabetes Association · 2014 · Diabetes Care
85. PPARs as Nuclear Receptors for Nutrient and Energy Metabolism
    Hong, Fan, Pan, Shijia, Guo, Yuan, Xu, Pengfei, Zhai, Yonggong · 2019 · Molecules
86. Effect of Aleglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus
    Abraham Michael Lincoff, Jean‐Claude Tardif, Gregory G. Schwartz, Stephen James Nicholls, Lars Rydén, Bruce Charles Neal, Klas Malmberg, Hans Wedel, John B. Buse, Robert R. Henry et al. · 2014 · JAMA
87. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
    Peter W.F. Wilson, Tamar S. Polonsky, Michael D. Miedema, Amit Khera, Andrzej Stanislaw Kosinski, Jeffrey T. Kuvin · 2018 · Journal of the American College of Cardiology
88. The Relationship between Lung Inflammation and Cardiovascular Disease
    Stephan F. van Eeden, Jonathon A Leipsic, S. F. Paul Man, Don D. Sin · 2012 · American Journal of Respiratory and Critical Care Medicine
89. Management of hypertriglyceridemia
    Vinaya Simha · 2020 · BMJ
90. 9. Cardiovascular Disease and Risk Management
    American Diabetes Association · 2017 · Diabetes Care
91. How Do Elevated Triglycerides and Low HDL-Cholesterol Affect Inflammation and Atherothrombosis?
    Welty, Francine K. · 2013 · Current Cardiology Reports
92. 2023 Chinese guideline for lipid management
    Jian‐Jun Li, Shui‐Ping Zhao, Dong Hui Zhao, Guoping Lü, Daoquan Peng, Jing Liu, Zhen‐Yue Chen, Yuan‐Lin Guo, Na‐Qiong Wu, Sheng-kai Yan et al. · 2023 · Frontiers in Pharmacology
93. From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk
    Shapiro, Michael D., Fazio, Sergio · 2016 · Circulation Research
94. American Association of Clinical Endocrinologists’ Comprehensive Diabetes Management Algorithm 2013 Consensus Statement
    Alan J. Garber, Martin J. Abrahamson, Joshua I. Barzilay, Lawrence Blonde, Zachary T. Bloomgarden, Michael A. Bush, Samuel E. Dagogo-Jack, Michael Davidson, DANIEL F. EINHORN, William Timothy Garvey et al. · 2013 · Endocrine Practice
95. Statin myopathy: A common dilemma not reflected in clinical trials
    Genaro Fernandez, Erica Sarah Spatz, Charles K. Jablecki, Paul S. Phillips · 2011 · Cleveland Clinic Journal of Medicine
96. Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial
    Ishibashi, Shun, Yamashita, Shizuya, Arai, Hidenori, Araki, Eiichi, Yokote, Koutaro, Suganami, Hideki, Fruchart, Jean-Charles, Kodama, Tatsuhiko · 2016 · Atherosclerosis
97. Disorders of lipid metabolism. Clinical Guidelines 2023
    Ежов Марат Владиславович, Valery V. Kukharchuk, И. В. Сергиенко, Asiiat S. Alieva, Mikhail Borisovich Antsiferov, Alexey A. Ansheles, Gurami G. Arabidze, Aronov Dm, G. P. Arutyunov, Н. М. Ахмеджанов et al. · 2023 · Russian Journal of Cardiology
98. Extreme nonfasting remnant cholesterol vs extreme LDL cholesterol as contributors to cardiovascular disease and all-cause mortality in 90000 individuals from the general population
    Varbo, Anette, Freiberg, Jacob J, Nordestgaard, Børge G · 2015 · Clinical Chemistry
99. Dual Peroxisome Proliferator–Activated Receptor α/δ Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects
    Bertrand Cariou, Rémy Hanf, S. Lambert-Porcheron, Yassine Zaïr, Valérie Sauvinet, Benoit Noël, Laurent Flet, Hubert Vidal, Bart Staels, Martine Laville · 2013 · Diabetes Care
100. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk
     Tardif, Jean-Claude, Karwatowska-Prokopczuk, Ewa, Amour, Eric St, Ballantyne, Christie M, Shapiro, Michael D, Moriarty, Patrick M, Baum, Seth J, Hurh, Eunju, Bartlett, Victoria J, Kingsbury, Joyce et al. · 2022 · European Heart Journal